Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) Combined With Anastrozole 5 y Versus Anastrozole 5 y as Adjuvant Hormonotherapy in Postmenopausal With Early Breast Cancer and Positive Hormone Receptors
Sponsor: AstraZeneca
Terminated
Unjustified decision of company that funded the trial.
A PHASE3 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 10 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE3
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Spanish Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alcorcón, Spain , Alcoy, Spain , Almería, Spain , Avilés, Spain , Badalona, Spain , Barbastro, Spain , Barcelona, Spain , Bilbao, Spain , Cadiz, Spain and 30 more locations